MGTX vs RGNX
MGTX: MeiraGTx is a vertically integrated genetic medicine company developing a pipeline of gene therapies and a unique riboswitch platform for dose-responsive, oral-small-molecule control of gene expression. RGNX: A clinical-stage gene therapy developer leveraging its proprietary AAV platform to create potentially curative, one-time treatments for serious genetic diseases.
Side-by-side fundamentals
| Metric | MGTX | RGNX | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $9.97 | $7.40 | |
| Market cap | $958M | $488M | |
| P/E as of 2026-10-20 | 11.46 | n/a | |
| Net margin FY2025, SEC XBRL | -140.3% | -113.8% | RGNX higher |
| Operating margin FY2025, SEC XBRL | -130.2% | -94.6% | RGNX higher |
| ROE FY2025, SEC XBRL | n/a | -188.7% | |
| ROA FY2025, SEC XBRL | -46.7% | -42.8% | RGNX higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +144.6% | +104.5% | MGTX higher |
| Revenue CAGR (3y) SEC XBRL | +141.0% | +14.8% | MGTX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.17 | 1.89 | |
| 1-year return as of 2026-10-20 close | +21.0% | -41.5% | MGTX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.